Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estimation of total kidney volume in autosomal dominant polycystic kidney disease.
Spithoven EM, van Gastel MD, Messchendorp AL, Casteleijn NF, Drenth JP, Gaillard CA, de Fijter JW, Meijer E, Peters DJ, Kappert P, Renken RJ, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium; DIPAK Consortium. Spithoven EM, et al. Among authors: messchendorp al. Am J Kidney Dis. 2015 Nov;66(5):792-801. doi: 10.1053/j.ajkd.2015.06.017. Epub 2015 Jul 31. Am J Kidney Dis. 2015. PMID: 26235803
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT; DIPAK Consortium. Lantinga MA, et al. Among authors: messchendorp al. Drug Saf. 2017 Feb;40(2):153-167. doi: 10.1007/s40264-016-0486-x. Drug Saf. 2017. PMID: 27995519 Free PMC article. Clinical Trial.
T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease.
van Gastel MDA, Messchendorp AL, Kappert P, Kaatee MA, de Jong M, Renken RJ, Ter Horst GJ, Mahesh SVK, Gansevoort RT; DIPAK Consortium. van Gastel MDA, et al. Among authors: messchendorp al. Abdom Radiol (NY). 2018 May;43(5):1215-1222. doi: 10.1007/s00261-017-1285-2. Abdom Radiol (NY). 2018. PMID: 28871393 Free PMC article.
The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
D'Agnolo HMA, Casteleijn NF, Gevers TJG, de Fijter H, van Gastel MDA, Messchendorp AL, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JFM, Zietse R, Gansevoort RT, Drenth JPH. D'Agnolo HMA, et al. Among authors: messchendorp al. Am J Nephrol. 2017;46(3):239-248. doi: 10.1159/000479436. Epub 2017 Sep 8. Am J Nephrol. 2017. PMID: 28881341 Clinical Trial.
Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, Losekoot M, Burgerhof JGM, Peters DJM, Gansevoort RT; DIPAK Consortium. Messchendorp AL, et al. Kidney Int Rep. 2017 Oct 14;3(2):291-301. doi: 10.1016/j.ekir.2017.10.004. eCollection 2018 Mar. Kidney Int Rep. 2017. PMID: 29725632 Free PMC article.
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators. Meijer E, et al. Among authors: messchendorp al. JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870. JAMA. 2018. PMID: 30422235 Free PMC article. Clinical Trial.
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators. van Aerts RMM, et al. Among authors: messchendorp al. Gastroenterology. 2019 Aug;157(2):481-491.e7. doi: 10.1053/j.gastro.2019.04.018. Epub 2019 Apr 22. Gastroenterology. 2019. PMID: 31022403 Clinical Trial.
39 results